![Fig. 6. Tumor antigen-specific IFN-γ production by responding splenocytes harvested from vaccinated mice (ELISPOT). / (A) Splenocyte IFN- γ production specific for tumor cells (EG.7-OVA) was shown in group 3 mice by ELISPOT assay. Spleen cells (5 × 106 cells/well) from each group were incubated for 24 hours with EG7-OVA or irrelevant tumor cell (EL4). (On day 21, group 3 vs group 2 [P < .05]; and groups 1, 4 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .01]; group 3 vs group 2 [P < .01]; group 3 vs group 4 [P < .005]). (B) These specific cells were also OVA peptide-specific CD8+ T cells. Spleen cells (5 × 106 cells/well) from each group were incubated for 36 hours with OVA peptide (SIINFEKL) or irrelevant peptide (SIINFKEL). These peptide-specific spots in each group were similar to the responding spots for EG7-OVA in Figure 6A. (On day 21, group 3 vs groups 2, 4 [P > .05]; group 1 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .0001]; group 3 vs group 2 [P < .0001]; group 3 vs group 4 [P < .0001]). Mean values are shown for 3 mice at each time point.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/7/10.1182_blood.v98.7.2143/5/h81911575006.jpeg?Expires=1735554386&Signature=VUhTtEaRD7~QHLRSEo3Hd4KPqIFFbr-Y1zcVKWShVJhxgD5k9SxmYPUhzUJmndHqsk-EJcKASZQNAUPtIdixISvN3vsTLnjyV67AQriH6WUmSlKGDUUhIk5V3ILhcuDhb4omBnnAm0rFqau9yhIm-nZVT24MdM9wYtkBaPVcv28u65o46jrV~mGuDN54LI1tLHJus-a-8qk1b0HeUo~aP~DMsf2kUAbCdubfbxWC3h6oMLAJwo-dxgV3Upj4DU2vj1Rpj-N4Z2VOb33DIUzIUKqiInvYSsxa7nnu4zH9Y0VKsLwb431ji02yR5wPF~Uk2d2~8Wo9c-kcW1uXN6S31w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Tumor antigen-specific IFN-γ production by responding splenocytes harvested from vaccinated mice (ELISPOT).
(A) Splenocyte IFN- γ production specific for tumor cells (EG.7-OVA) was shown in group 3 mice by ELISPOT assay. Spleen cells (5 × 106 cells/well) from each group were incubated for 24 hours with EG7-OVA or irrelevant tumor cell (EL4). (On day 21, group 3 vs group 2 [P < .05]; and groups 1, 4 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .01]; group 3 vs group 2 [P < .01]; group 3 vs group 4 [P < .005]). (B) These specific cells were also OVA peptide-specific CD8+ T cells. Spleen cells (5 × 106 cells/well) from each group were incubated for 36 hours with OVA peptide (SIINFEKL) or irrelevant peptide (SIINFKEL). These peptide-specific spots in each group were similar to the responding spots for EG7-OVA in Figure 6A. (On day 21, group 3 vs groups 2, 4 [P > .05]; group 1 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .0001]; group 3 vs group 2 [P < .0001]; group 3 vs group 4 [P < .0001]). Mean values are shown for 3 mice at each time point.
